© 1995 by Oxford University Press
Journal of the National Cancer Institute, Vol. 87, No. 14, 1077-1081,
July 19, 1995
© 1995 Oxford University Press
Paclitaxel Disposition in Plasma and Central Nervous Systems of Humans and Rats With Brain Tumors
Department of Medicine, Brown University School of Medicine Providence, RI
Department of Radiation Therapy, Brown University School of Medicine Providence, RI
Department of Neurosurgery, Brown University School of Medicine Providence, RI
Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy
Division of Hematology—Oncology, Department of Medicine, University of Maryland School of Medicine
Division of Developmental Therapeutics, University of Maryland Cancer Center Baltimore, MD
*Correspondence to: Merrill J. Egorin, M.D., Division of Developmental Therapeutics, University of Maryland Cancer Center, 655 W. Baltimore St., Baltimore, MD 21201.
Background: Paclitaxel (Taxol) has been shown to sensitize some malignant cells to the effects of radiation. A number of clinical protocols, combining paclitaxel with radiation therapy, have been designed to exploit this phenomenon. The radiation-potentiating effect of paclitaxel is likely dependent on the ability of the drug to penetrate the tissue being radiated. Paclitaxel is known to have limited access to the central nervous system (CNS) of rats and mice, but its ability to penetrate malignant tissue in the CNS is inadequately documented. Purpose: Our purpose was to examine the concentrations of paclitaxel in the cerebrospinal fluid (CSF) of patients with CNS malignancies and in normal and malignant tissues from the brains of Fischer rats bearing the C6 rat glioma and then to compare those paclitaxel concentrations with concomitant paclitaxel concentrations in the plasma of those same patients and animals. Methods: Four patients were treated with 3-hour infusions of paclitaxel at doses between 90 and 200 mg/m2. Plasma and CSF were sampled at 0.33, 1.5, 3.25, 5, 6, and 24 hours after initiation of the paclitaxel infusion. Four Fischer rats had 20 000 C6 glioma cells stereotactically implanted into their right frontal lobes; 28 days later, they were given 3-hour infusions of paclitaxel at 10 mg/kg. Plasma was sampled during the paclitaxel infusion. At the completion of the infusion, rats were killed, and portions of their normal and malignant CNS tissues were removed for histologic assessment. Concentrations of paclitaxel in plasma, CSF, and brain tissue were determined with high-pressure liquid chromatography. Results: Plasma pharmacokinetics of paclitaxel in patients with brain tumors were comparable to those previously described in patients with other malignancies. Paclitaxel could be measured in CSF of all patients, but concentrations were very low. Peak paclitaxel concentrations in CSF ranged between 5 and 83 nM and occurred between 3.25 and 5 hours after initiation of the paclitaxel infusion. Peak paclitaxel concentrations in CSF were between 0.12% and 8.3% of those present in concomitant plasma samples. Paclitaxel was not detectable in the normal or malignant CNS tissue of any rat, despite the fact that plasma concentrations of paclitaxel at the time of tissue acquisition ranged from 0.62 to 153 µM. Conclusions: Paclitaxel has only limited access to the CSF of patients with CNS malignancies and to normal and malignant CNS tissues of rats bearing brain tumors. Implications: The utility of combining paclitaxel with radiation therapy to treat CNS malignancies should be considered in light of the documented limited access of paclitaxel to the CNS. [J Natl Cancer Inst 87:1077–1081, 1995]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. M. Lichtman, D. Hollis, A. A. Miller, G. L. Rosner, C. A. Rhoades, E. P. Lester, F. Millard, J. Byrd, S. A. Cullinan, D. M. Rosen, et al. Prospective Evaluation of the Relationship of Patient Age and Paclitaxel Clinical Pharmacology: Cancer and Leukemia Group B (CALGB 9762) J. Clin. Oncol., April 20, 2006; 24(12): 1846 - 1851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Miller, G. L. Rosner, M. J. Egorin, D. Hollis, S. M. Lichtman, M. J. Ratain, and for the Cancer and Leukemia Group B Prospective Evaluation of Body Surface Area as a Determinant of Paclitaxel Pharmacokinetics and Pharmacodynamics in Women with Solid Tumors: Cancer and Leukemia Group B Study 9763 Clin. Cancer Res., December 15, 2004; 10(24): 8325 - 8331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Gallo, S. Li, P. Guo, K. Reed, and J. Ma The Effect of P-glycoprotein on Paclitaxel Brain and Brain Tumor Distribution in Mice Cancer Res., August 15, 2003; 63(16): 5114 - 5117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Li, W. Dang, B. M. Tyler, G. Troiano, T. Tihan, H. Brem, and K. A. Walter Polilactofate Microspheres for Paclitaxel Delivery to Central Nervous System Malignancies Clin. Cancer Res., August 1, 2003; 9(9): 3441 - 3447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shingu, K. Yamada, N. Hara, K. Moritake, H. Osago, M. Terashima, T. Uemura, T. Yamasaki, and M. Tsuchiya Synergistic Augmentation of Antimicrotubule Agent-induced Cytotoxicity by a Phosphoinositide 3-Kinase Inhibitor in Human Malignant Glioma Cells Cancer Res., July 15, 2003; 63(14): 4044 - 4047. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Ziske, B. Schottker, M. Gorschluter, U. Mey, R. Kleinschmidt, U. Schlegel, T. Sauerbruch, and I. G. H. Schmidt-Wolf Acute transient encephalopathy after paclitaxel infusion: report of three cases Ann. Onc., April 1, 2002; 13(4): 629 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Bafaloukos, H. Gogas, V. Georgoulias, E. Briassoulis, G. Fountzilas, E. Samantas, Ch. Kalofonos, D. Skarlos, A. Karabelis, and P. Kosmidis Temozolomide in Combination With Docetaxel in Patients With Advanced Melanoma: A Phase II Study of the Hellenic Cooperative Oncology Group J. Clin. Oncol., January 15, 2002; 20(2): 420 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Fracasso, P. Westerveldt, C. A. Fears, D. M. Rosen, E. G. Zuhowski, L. A. Cazenave, M. Litchman, and M. J. Egorin Phase I Study of Paclitaxel in Combination With a Multidrug Resistance Modulator, PSC 833 (Valspodar), in Refractory Malignancies J. Clin. Oncol., March 1, 2000; 18(5): 1124 - 1124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Poujol, F. Pinguet, F. Bressole, M. Boustta, and M. Vert Molecular Microencapsulation: Paclitaxel Formations in Aqueous Medium Using Hydrophobized Poly(L-Lysine Citramide Imide) Journal of Bioactive and Compatible Polymers, March 1, 2000; 15(2): 99 - 114. [Abstract] [PDF]
|
|
|
|
 |
|
 S. H. Tseng, M. S. Bobola, M. S. Berger, and J. R. Silber Characterization of paclitaxel (Taxol(R)) sensitivity in human glioma- and medulloblastoma-derived cell lines Neuro-oncol, April 1, 1999; 1(2): 101 - 108. [Abstract] [PDF]
|
|
|
|
|
|
Y. Nieto, P. J. Cagnoni, S. I. Bearman, E. J. Shpall, S. Matthes, T. DeBoom, A. Baron, and R. B. Jones Acute Encephalopathy: A New Toxicity Associated with High-Dose Paclitaxel Clin. Cancer Res., March 1, 1999; 5(3): 501 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. F. Lam, C. J. Chan, and J. G Kuhn Review : Pharmacokinetics and pharmacodynamics of the taxanes Journal of Oncology Pharmacy Practice, June 1, 1997; 3(2): 76 - 93. [Abstract] [PDF]
|
|